Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Pharmacological assessment of the contribution of the arterial baroreflex to sympathetic discharge patterns in healthy humans
Limberg, Jacqueline K. , Ott, Elizabeth P., Holbein, Walter W., Baker, Sarah E. , Curry, Timothy B. , Nicholson, Wayne T. , Shoemaker, J. Kevin , Shoemaker, J Kevin , Joyner, Michael J. , Baker, Sarah E

Mayo Clinic

Journal of Neurophysiology | February 28, 2018 | Volume: 119 | Issue: 6 | Pages: 2166-2175

10.1152/jn.00935.2017 | PMID 29488839 Get It

To study how changes in baroreceptor afferent activity affect patterns of sympathetic neural activation, we manipulated arterial blood pressure with intravenous nitroprusside (NTP) and phenylephrine (PE) and measured action potential (AP) patterns with wavelet-based methodology. We hypothesized that 1) baroreflex unloading (NTP) would increase firing of low-threshold axons and recruitment of latent axons and 2) baroreflex loading (PE) would decrease firing of low-threshold axons. Heart rate (HR, ECG), arterial blood pressure (BP, brachial catheter), and muscle sympathetic nerve activity (MSNA, microneurography of peroneal nerve) were measured at baseline and during steady-state systemic, intravenous NTP (0.5–1.2 µg·kg−1·min−1, n = 13) or PE (0.2–1.0 µg·kg−1·min−1, n = 9) infusion. BP decreased and HR and integrated MSNA increased with NTP ( P < 0.01). AP incidence (326 ± 66 to 579 ± 129 APs/100 heartbeats) and AP content per integrated burst (8 ± 1 to 11 ± 2 APs/burst) increased with NTP ( P < 0.05). The firing probability of low-threshold axons increased with NTP, and recruitment of high-threshold axons was observed (22 ± 3 to 24 ± 3 max cluster number, 9 ± 1 to 11 ± 1 clusters/burst; P < 0.05). BP increased and HR and integrated MSNA decreased with PE ( P < 0.05). PE decreased AP incidence (406 ± 128 to 166 ± 42 APs/100 heartbeats) and resulted in fewer unique clusters (15 ± 2 to 9 ± 1 max cluster number, P < 0.05); components of an integrated burst (APs or clusters per burst) were not altered ( P > 0.05). These data support a hierarchical pattern of sympathetic neural activation during manipulation of baroreceptor afferent activity, with rate coding of active neurons playing the predominant role and recruitment/derecruitment of higher-threshold units occurring with steady-state hypotensive stress. NEW & NOTEWORTHY To study how changes in baroreceptor afferent activity affect patterns of sympathetic neural activation, we manipulated arterial blood pressure with intravenous nitroprusside and phenylephrine and measured sympathetic outflow with wavelet-based methodology. Baroreflex unloading increased sympathetic activity by increasing firing probability of low-threshold axons (rate coding) and recruiting new populations of high-threshold axons. Baroreflex loading decreased sympathetic activity by decreasing the firing probability of larger axons (derecruitment); however, the components of an integrated burst were unaffected.
Expression of Embryonic Lethal Abnormal Vision (ELAV)-Like Protein HuR and Cyclooxygenase-2 (COX-2) in Ewing Sarcoma
Do, Sung‐Im , Araujo, Eduard Santini, Kalil, Ricardo K. , Bacchini, Patrizia, Bertoni, Franco, Unni, K. Krishnan, Park, Yong-Koo , Araujo, Eduardo Santini

Mayo Clinic

Tumori Journal | February 27, 2018 | Volume: 94 | Issue: 3 | Pages: 347-350

10.1177/030089160809400310 | PMID 18705402 Get It

Aims and Background HuR is a member of the family of ELAV (embryonic lethal abnormal vision)-like proteins that stabilize several cellular mRNAs by binding to AU-rich elements in the 3’ untranslated region of the mRNA. Cyclooxygenase-2 (COX-2) is a well known enzyme that promotes tumor growth and metastasis. Recent studies have shown that HuR can stabilize the mRNA of COX-2, and cytoplasmic expression of HuR is associated with increased COX-2 expression in some cancers. The aim of this study was to investigate the correlation between COX-2 and HuR in Ewing sarcoma. Methods The expression patterns for HuR and COX-2 were assessed via immunochemical analysis of 70 Ewing sarcoma samples. Results Nuclear HuR expression was observed in 12 of 70 (17.1%) cases, but cytoplasmic expression was not observed. COX-2 expression was seen in 25 of 70 (35.7%) samples. Nuclear HuR and COX-2 were simultaneously expressed in 8 of 70 (11.4%) samples. The expression of nuclear HuR was significantly associated with COX-2 expression (P = 0.014). Neither HuR nor COX-2 expression showed a correlation with age or sex. Conclusions COX-2 expression in Ewing sarcoma may not be directly related to mRNA stabilization by HuR. However, a correlation between COX-2 expression and nuclear HuR expression through indirect mRNA stabilization can be suggested.
Phase I/II trial of pembrolizumab in combination with binimetinib in unresectable locally advanced or metastatic triple negative breast cancer.
Chumsri, Saranya , Polley, Mei‐Yin C. , O’Sullivan, Ciara C. , Colón‐Otero, Gerardo , Knutson, Keith L. , Thompson, E. Aubrey , Moreno‐Aspitia, Alvaro , Anderson, Sarah L. , Knutson, Keith L.

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 5_suppl | Pages: TPS17-TPS17

10.1200/jco.2018.36.5_suppl.tps17 Get It

TPS17 Background: Emerging studies suggest that breast cancer, particularly triple negative breast cancer (TNBC), may be sensitive to immunotherapy. However, the response rate of single agent immune checkpoint blockade agent in TNBC is rather low. Previous genomic study in residual tumor after neoadjuvant chemotherapy showed inverse correlations between MEK activation signature and the amount of tumor infiltrating lymphocytes (TILs) in residual disease samples as well as poor outcome. Preclinical study also showed that the combination of MEK inhibitor and anti-PD-L1 antibody in mouse model can eradicate TNBC tumors. Methods: This is a single arm, Phase I/II trial of Pembrolizumab (P) in combination with Binimetinib (B) in patients with unresectable locally advanced or metastatic TNBC. This trial is currently opened for accrual at Mayo Clinic in Florida and Minnesota. Patients with TNBC defined as ER ≤ 10% and PR ≤ 10% who received ≤ 3 prior lines with measurable disease will be enrolled. The primary objective of the Phase I part is to determine the maximum tolerated dose of B in combination with P and for the Phase II part is objective response rate (ORR) by RECIST criteria. The secondary endpoints include ORR by irRECIST, progression free survival, and overall survival. The total sample size is 15-38 patients with 6-12 patients in Phase I with 2 dose levels and 9-26 patients in Phase II. Simon’s Two-Stage Optimal Design is used to test the null hypothesis that this two-drug combination has an ORR of at most 15% vs. the alternative hypothesis that it has an ORR of at least 35%. Patients will receive single agent B for 2 weeks prior to starting P. A mandatory biopsy will be performed before starting B and an optional biopsy will be performed after 2 weeks of B. Tumor tissue will be evaluated for the amount and phenotypes of TILs, PD-L1 expression, and gene expression analysis using PanCancer Immune Profiling Panel, and PDJ amplification. Peripheral blood will be evaluated for circulating immunoregulatory cells, cytokine profiling, circulating tumor cells (CTCs), as well as p-ERK and PD-L1 expression on CTCs. Clinical trial information: NCT03106415.
Internet Use by Gynecologic Oncology Patients and Its Relationship with Anxiety
Corrales, Dalia M, Wells, Ali , Breitkopf, Carmen Radecki , Peña, Gabriela de la, Kaplan, Alan L., King, Lorrie S, Robazetti, Sonia C., Dinh, Tri A., Wells, Ali E, Radecki Breitkopf, Carmen, Corrales, Dalia M

Mayo Clinic

Journal of Health Communication | February 23, 2018 | Volume: 23 | Issue: 3 | Pages: 299-305

10.1080/10810730.2018.1442529 | PMID 29474124 Get It

Kinematics of semi-constrained total elbow arthroplasty
An, K-N., Korinek, Sarah, Morrey, BF, O’Driscoll, Shawn W. , Morrey, BF

Mayo Clinic

The Journal of Bone and Joint Surgery. British volume | February 21, 2018 | Volume: 74-B | Issue: 2 | Pages: 297-299

10.1302/0301-620x.74b2.1544973 | PMID 1544973 Get It

We used 11 cadaver elbows and a three-dimensional electromagnetic tracking device to record elbow movements before and after implantation of a 'loose-hinged' elbow prosthesis (modified Coonrad). During simulated active motion there was a maximum of 2.7 degrees (+/- 1.5 degrees) varus/valgus laxity in the cadaver joints. This increased slightly after total elbow arthroplasty to 3.8 degrees (+/- 1.4 degrees). These values are lower than those recorded for the cadaver joints and for the prostheses at the limits of their varus/valgus displacements, indicating that both behave as 'semi-constrained' joints under physiological conditions. They suggest that the muscles absorb some of the forces and moments that in a constrained prosthesis would be transferred to the prosthesis-bone interface.
Determinants of hematology-oncology trainees' postfellowship career pathways with a focus on nonmalignant hematology
Marshall, Ariela L. , Jenkins, Sarah M. , Gitlin, Scott D., Mıkhael, Joseph , Marshall, Ariela

Mayo Clinic

Blood Advances | February 20, 2018 | Volume: 2 | Issue: 4 | Pages: 361-369

10.1182/bloodadvances.2017013722 | PMID 29463548 Get It

Key Points Hematology-oncology fellowship graduates spend a relatively small proportion of their time practicing nonmalignant hematology. Factors that may increase interest in nonmalignant hematology include better access to mentors and improved opportunities for career growth.
Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer
Forero, Andres , Mita, Monica , Miller, KD, Weise, Amy, Krop, Ian E. , Burris, Howard A. , Tsai, Meng‐Chen , Liu, MC, Hurvitz, SA, Wilks, Sharon , Diab, Sami, Han, HS, Nanda, Rita , O’Shaughnessy, J., Modi, Shanu , Pusztai, Lajos , Kalinsky, Kevin M. , Ademuyiwa, Foluso O. , Kato, Gregory J. , Kostic, Aleksandar David , Li, Michael , Specht, Jennifer M.

Mayo Clinic

Cancer Research | February 15, 2018 | Volume: 78 | Issue: 4_Supplement | Pages: PD3-14-PD3-14

10.1158/1538-7445.sabcs17-pd3-14 Get It

Abstract Background LIV-1, a transmembrane protein and downstream target of STAT3, is highly expressed in breast cancer cells. It is associated with lymph node involvement and metastatic progression. SGN-LIV1A is an anti-LIV-1 antibody conjugated via a protease-cleavable linker to monomethyl auristatin E (MMAE). Upon binding to cell-surface LIV-1, SGN-LIV1A is internalized and releases MMAE, which disrupts microtubulin and induces apoptosis. Methods This ongoing, phase 1 study evaluates safety, tolerability, pharmacokinetics, and antitumor activity of SGN-LIV1A (q3wks IV) in women with LIV-1-positive, unresectable, locally advanced or metastatic breast cancer (LA/MBC) (NCT01969643). Patients (pts) with measurable disease and ≥2 prior cytotoxic regimens for LA/MBC are eligible. Pts with ≥ Grade 2 neuropathy are excluded. Response is assessed per RECIST v1.1; pts with stable disease (SD) or better can continue treatment until disease progression or intolerable toxicity. At completion of dose escalation in hormone receptor-positive/HER2-negative (HR+/HER2–) and triple-negative (TN) pts, expansion cohorts were opened to further evaluate safety and antitumor activity of monotherapy in TN pts. Tumor biopsies are evaluated for LIV-1 expression. Results To date, 69 pts (18 HR+/HER2–, 51 TN) have received a median of 3 cycles (range, 1–12) of SGN-LIV1A at doses of 0.5–2.8 mg/kg. Median age was 56 yrs. Pts had a median of 3 prior cytotoxic regimens for LA/MBC; 58 had visceral disease and 37 had bone metastases. No dose-limiting toxicities (DLTs) occurred in 19 DLT-evaluable pts; maximum tolerated dose was not exceeded at 2.8 mg/kg. Expansion cohorts of TN pts were opened at 2.0 and 2.5 mg/kg. Treatment-emergent adverse events (AEs) reported in ≥25% of pts were fatigue (59%), nausea (51%), peripheral neuropathy (44%), alopecia (36%), decreased appetite (33%), constipation (30%), abdominal pain, diarrhea, and neutropenia (25% each). Most AEs were Grade 1/2; AEs ≥ Grade 3 included neutropenia (25%) and anemia (15%). Febrile neutropenia occurred in 2 pts whose total dose exceeded 200 mg per cycle, including 1 treatment-related death due to sepsis. No other treatment-related deaths occurred on-study. Seven pts discontinued treatment due to AEs. In dose escalation, activity was observed in 17 efficacy evaluable (EE) HR+/HER2- pts, with a disease control rate (DCR= CR+PR+SD) of 59% (10 SD), including 1 pt with SD ≥24 wks. Among the 44 EE TN pts (dose escalation plus expansion cohorts), the objective response rate (ORR) was 32% (14 PR) with a confirmed PR rate of 21%, DCR was 64% (14 PR, 14 SD), and clinical benefit rate (CBR=CR+PR+SD ≥24 wks) was 36% (16 pts). For TN pts, median PFS was 11.3 wks (95% CI: 6.1, 17.1); 10 pts remain on treatment. Of 631 MBC tumor samples of all clinical subtypes evaluated for LIV-1, 91% were positive; 75% had moderate-to-high expression (H-score ≥100). Conclusions LIV-1 is expressed in almost all MBC tumors. SGN-LIV1A monotherapy was generally well tolerated and showed encouraging antitumor activity in heavily pretreated TN MBC, with a PR rate of 32%, confirmed PR rate of 21%, and CBR (≥24 wks) of 36%. Response duration data continue to evolve. Enrollment continues in the TN monotherapy expansion cohort. Citation Format: Modi S, Pusztai L, Forero A, Mita M, Miller KD, Weise A, Krop I, Burris III H, Kalinsky K, Tsai M, Liu MC, Hurvitz SA, Wilks S, Ademuyiwa F, Diab S, Han HS, Kato G, Nanda R, O'Shaughnessy J, Kostic A, Li M, Specht J. Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD3-14.
Outcome measures in coeliac disease trials: the Tampere recommendations
Ludvigsson, Jonas F. , Ciacci, Carolina , Green, Peter H.R., Kaukinen, Katri , Korponay‐Szabó, Ilma R. , Kurppa, Kalle , Lundin, Knut Erik Aslaksen, Mäki, Markku , Popp, Alina , Reilly, Norelle R., Rodríguez‐Herrera, Alfonso , Sanders, David S. , Schuppan, Detlef, Sleet, Sarah, Voorhees, Kristin, Walker, Marjorie M. , Leffler, Daniel A. , Ciacci, Carolina , Green, Peter H.R. , Murray, Joseph A. , Taavela, Juha

Mayo Clinic

Gut | February 13, 2018 | Volume: 67 | Issue: 8 | Pages: 1410-1424

10.1136/gutjnl-2017-314853 | PMID 29440464 Get It

Objective A gluten-free diet is the only treatment option of coeliac disease, but recently an increasing number of trials have begun to explore alternative treatment strategies. We aimed to review the literature on coeliac disease therapeutic trials and issue recommendations for outcome measures. Design Based on a literature review of 10 062 references, we (17 researchers and 2 patient representatives from 10 countries) reviewed the use and suitability of both clinical and non-clinical outcome measures. We then made expert-based recommendations for use of these outcomes in coeliac disease trials and identified areas where research is needed. Results We comment on the use of histology, serology, clinical outcome assessment (including patient-reported outcomes), quality of life and immunological tools including gluten immunogenic peptides for trials in coeliac disease. Conclusion Careful evaluation and reporting of outcome measures will increase transparency and comparability of coeliac disease therapeutic trials, and will benefit patients, healthcare and the pharmaceutical industry.
Measuring cognition and function in the preclinical stage of Alzheimer's disease
Weıntraub, Sandra , Farias, Sarah Tomaszewski , Goldberg, Terry E. , Hendrix, James A. , Jaeger, Judith , Park, Denise C. , Ropacki, Michael T., Sikkes, Sietske A.M. , Bain, Lisa J. , Brashear, Robert, Budur, Kumar, Graf, Ana, Martényi, Ferenc, Storck, Marta Segardahl, Randolph, Christopher , Carrillo, María C. , Knopman, David S. , Langbaum, Jessica B. S. , Welsh-Bohmer, Kathleen Anne

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | February 13, 2018 | Volume: 4 | Issue: 1 | Pages: 64-75

10.1016/j.trci.2018.01.003 | PMID 29955653 Get It

Abstract The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.
Lingual Pressure as a Clinical Indicator of Swallowing Function in Parkinson's Disease
Pitts, Laura L. , Morales, Sarah, Stierwalt, Julie A. G.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | February 2, 2018 | Volume: 61 | Issue: 2 | Pages: 257-265

10.1044/2017_jslhr-s-17-0259 | PMID 29396576 Get It

PurposeSwallowing impairment, or dysphagia, is a known contributor to reduced quality of life, pneumonia, and mortality in Parkinson's disease (PD). However, the contribution of tongue dysfunction, specifically inadequate pressure generation, to dysphagia in PD remains unclear. Our purpose was to determine whether lingual pressures in PD are (a) reduced, (b) reflect medication state, or are (c) consistent with self-reported diet and swallowing function.MethodTwenty-eight persons with idiopathic PD (PwPD) and 28 age- and sex-matched controls completed lingual pressure tasks with the Iowa Oral Performance Instrument. PwPD were tested during practically defined ON and OFF dopaminergic medication states. Participants were also stratified into three sex- and age-matched cohorts (7 men, 5 women): (a) controls, (b) PwPD without self-reported dysphagia symptoms or diet restrictions, and (c) PwPD with self-reported dysphagia symptoms with or without diet restrictions.ResultsPwPD exhibited reduced tongue strength and used elevated proportions of tongue strength during swallowing compared with controls (p< .05) without an effect of medication state (p> .05). Reduced tongue strength distinguished PwPD with self-reported dysphagia symptoms from PwPD without reported symptoms or diet restrictions (p= .045) and controls (p= .002).ConclusionTongue strength was significantly reduced in PwPD and did not differ by medication state. Tongue strength differentiated between PwPD with and without self-reported swallowing symptoms. Therefore, measures of tongue strength and swallowing pressures may serve as clinical indicators for further dysphagia evaluation and may promote early diagnosis and management of dysphagia in PD.